Cannabis Companies Eye Major Exchange Listings Under New Federal Bill

A new federal bill under congressional consideration would allow cannabis companies to list on major U.S. stock exchanges, potentially ending years of regulatory exile that has forced operators onto over-the-counter markets and Canadian exchanges. The legislation represents the most direct path yet for cannabis companies to access the liquidity and institutional investor base that traditional exchanges provide.

Current federal scheduling restrictions prevent cannabis operators from listing on the New York Stock Exchange or NASDAQ, forcing companies like Curaleaf Holdings (CURLF) and Green Thumb Industries (GTBIF) to trade on the Canadian Securities Exchange or U.S. OTC markets. This regulatory barrier has created a valuation discount compared to other consumer goods sectors, with limited institutional participation constraining capital access and trading volumes.

The exchange listing provision could trigger substantial revaluations across the sector, as institutional investors including pension funds and mutual funds gain regulatory clarity to establish cannabis positions. Multi-state operators currently trade at significant discounts to traditional retail and consumer product companies despite generating comparable revenue growth rates. Access to major exchanges typically increases trading volumes by 300-500% while reducing bid-ask spreads that currently penalize cannabis investors.

Beyond immediate stock performance implications, exchange access would fundamentally alter cannabis companies' capital formation strategies. The sector has relied heavily on debt financing and private placements due to limited public market access, often accepting higher capital costs. Major exchange listings would enable traditional equity raises, secondary offerings, and potentially inclusion in broad market indices, expanding the investor base beyond specialized cannabis funds.

The timing aligns with broader federal cannabis reform momentum, as state-legal markets now generate over $25 billion in annual sales while federal policy lags behind economic reality. However, the bill faces the same political headwinds that have stalled comprehensive cannabis reform, with Senate passage remaining uncertain despite House support. Cannabis operators continue building scale in anticipation of federal changes, with leading MSOs now approaching $1 billion in annual revenue while trading at fractions of comparable consumer goods multiples.